BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29020174)

  • 1. The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection.
    Erlandson KM; Kitch D; Wester CW; Kalayjian RC; Overton ET; Castillo-Mancilla J; Koletar SL; Benson CA; Campbell TB; Robertson K; Lok JJ
    Clin Infect Dis; 2017 Nov; 65(12):2042-2049. PubMed ID: 29020174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study.
    Kang JH; Kao LT; Lin HC; Wang TJ; Yang TY
    PLoS One; 2018; 13(6):e0199981. PubMed ID: 29953536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Atherosclerosis; 2019 Oct; 289():109-117. PubMed ID: 31491742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
    De Spiegeleer A; Bronselaer A; Teo JT; Byttebier G; De Tré G; Belmans L; Dobson R; Wynendaele E; Van De Wiele C; Vandaele F; Van Dijck D; Bean D; Fedson D; De Spiegeleer B
    J Am Med Dir Assoc; 2020 Jul; 21(7):909-914.e2. PubMed ID: 32674818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
    Ma J; Khalidi N; Wierzbicki O; Alqutami A; Ioannidis G; Pagnoux C
    Int J Rheum Dis; 2020 Aug; 23(9):1233-1239. PubMed ID: 32776676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
    Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
    Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.
    Sorbets E; Labreuche J; Simon T; Delorme L; Danchin N; Amarenco P; Goto S; Meune C; Eagle KA; Bhatt DL; Steg PG
    Eur Heart J; 2014 Jul; 35(26):1760-8. PubMed ID: 24616336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes.
    Raebel MA; Dyer W; Nichols GA; Goodrich GK; Schmittdiel JA
    Pharmacotherapy; 2017 Oct; 37(10):1204-1214. PubMed ID: 28752555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
    Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
    BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
    Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.
    Tjia J; Briesacher BA
    J Am Geriatr Soc; 2008 Oct; 56(10):1879-86. PubMed ID: 18771456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.
    Shin J; Kim H; Yim HW; Kim JH; Lee S; Kim HS
    J Clin Pharm Ther; 2022 Jan; 47(1):97-103. PubMed ID: 34668200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.